J 2013

A pilot study on separation of new drugs for treatment of leukemia by capillary zone electrophoresis

HORSKÁ, Jana, Pavlína GINTEROVÁ, Juraj ŠEVČÍK and Jan PETR

Basic information

Original name

A pilot study on separation of new drugs for treatment of leukemia by capillary zone electrophoresis

Name in Czech

Pilotní studie separace nových prtinádorových léčiv pomocí CZE

Authors

HORSKÁ, Jana, Pavlína GINTEROVÁ, Juraj ŠEVČÍK and Jan PETR

Edition

Chemické Listy, Praha, 2013, 0009-2770

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10406 Analytical chemistry

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 0.196

Organization unit

Faculty of Education

UT WoS

000328730800037

Keywords in English

CHRONIC MYELOID-LEUKEMIA; IMATINIB MESYLATE

Tags

International impact, Reviewed
Změněno: 17/1/2019 08:10, Dana Nesnídalová

Abstract

V originále

Imatinib, bosutinib, dasatinib, pazopanib, erlotinib, canertinib and vatalanib are new important anticancer drugs, especially for treatment chronic myeloid leukemia. All of these substances without imatinib are being tested in clinical trials with very promising results. Imatinib is the standard first-line therapy at chronic myeloid leukemia for almost 10 years. The aim of our work was to develop the fastest separation of all these drugs in one run. According to the structure of drugs, capillary zone electrophoresis was chosen. The separation was performed with a background electrolyte containing 100 mM phosphoric acid, adjusted by sodium hydroxide to pH 2.75.